Biotech entity

Arbutus Biopharma

Company ABUS

Every one of those 1 sits in a single category, pharma. Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 1 of these 1 story. Arbutus Biopharma appears in 1 tracked Biotech story from March 4, 2026.

Last mentioned: 4d ago

Entity pulse

Recent coverage · Arbutus Biopharma

1 story
7 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Arbutus Biopharma

Every one of those 1 sits in a single category, pharma. Arbutus Biopharma is most often covered alongside Genevant Sciences, which appears in 1 of these 1 story. Arbutus Biopharma appears in 1 tracked Biotech story from March 4, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Arbutus Biopharma. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Settlement Reached

    Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.

  2. Claims Construction

    Court rulings on patent definitions provide momentum for the plaintiffs.

  3. Lawsuit Filed

    Arbutus and Genevant sue Moderna for patent infringement in Delaware federal court.

  4. Vaccine Launch

    Moderna receives EUA for Spikevax, utilizing LNP technology for delivery.

Stories mentioning Arbutus Biopharma 1

Pharma Neutral

Moderna to Pay Roivant $2.25 Billion to Settle mRNA Patent Litigation

Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.

2 sources

Arbutus Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.